Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN (AMGN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/16/2018 02/20/2018 02/21/2018 02/22/2018 02/23/2018 Date
183.55(c) 182.98(c) 182.43(c) 182.45(c) 186.67(c) Last
4 365 816 4 078 367 4 054 587 3 868 197 3 972 018 Volume
-0.03% -0.31% -0.30% +0.01% +2.31% Change
More quotes
Financials ($)
Sales 2018 22 600 M
EBIT 2018 11 508 M
Net income 2018 8 181 M
Finance 2018 6 263 M
Yield 2018 2,79%
Sales 2019 22 600 M
EBIT 2019 11 690 M
Net income 2019 8 556 M
Finance 2019 10 160 M
Yield 2019 2,96%
P/E ratio 2018 15,58
P/E ratio 2019 14,36
EV / Sales2018 5,58x
EV / Sales2019 5,41x
Capitalization 132 B
More Financials
Company
Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses.The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.Its products include... 
Sector
Pharmaceuticals
Calendar
04/24Earnings Release
More about the company
Surperformance© ratings of Amgen
Trading Rating : Investor Rating :
More Ratings
Latest news on AMGEN
02:21pAMGEN : Receives Positive Opinion Expanding Use Of XGEVA® (denosumab) To Cover P..
PR
02/21Merck to buy virus-based cancer drug firm Viralytics for $394 million
RE
02/21AMGEN : AMGN) Stock Price Declined While Profund Advisors LLC Upped by $3.94 Mil..
AQ
02/20AMGEN : Health and Human Services Department (HHS); Food and Drug Administration..
AQ
02/19Rare Haematology Market Trend to 2025 Profiling PRA Health Sciences, Bayer He..
AQ
02/16NOVARTIS : readies to auction U.S. generic pills business - sources
RE
02/15AMGEN : Results From Phase 3 XGEVA® Denosumab Study In Patients With Multiple My..
AQ
02/15AMGEN : Researchers at Amgen Have Reported New Data on Oligopeptides (Rapid scre..
AQ
02/14AMGEN : Announces FDA Advisory Committee Meeting To Review Potential New Use Of ..
PU
02/14+50% CAGR TO BE ACHIEVED BY BIOSIMIL : Global Biosimilars Market – Know In..
AQ
More news
Sector news : Pharmaceuticals - NEC
01:46pPUMA BIOTECHNOLOGY : EU panel recommends against nod for Puma Biotech's breast c..
RE
12:30pSANOFI : Says U.S. Waiting Period for Bioverativ Has Expired
DJ
11:10aSHIRE : FDA to Conduct Priority Review of Shire Genetic-Disorder Drug
DJ
08:48aNOVARTIS : Greek Parliament Approves Bribery and Price Fix Inquiry on Novartis -..
DJ
02/22NOVARTIS : Greek Parliament Investigates Politicians in Novartis Bribery Probe
DJ
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on AMGEN 
AMGEN - 2017
Back on key levels based on weekly price data
BUY
AMGEN, INC. - 2016
Expectation of a turn-around
BUY
More Strategies
Latest Tweets
06:12pAmgen : Launches First Research Grant Competition  
03:46pPharmalot.. Pharmalittle.. Good Morning.. has the Novartis bribe probe hit a .. 
03:09pAmgen Receives Positive Opinion Expanding Use Of XGEVA® (denosumab) To Cover .. 
02:46pEuropean advisory group backs expanded use of Amgen's Xgeva  
02:24p$AMGN Amgen Receives Positive Opinion Expanding Use Of XGEVA® (denosumab) To .. 
More tweets
Qtime:174
News from SeekingAlpha
09:01aAMGEN : Outlook 
08:46aEuropean advisory group backs expanded use of Amgen's Xgeva 
02/22IRA Portfolio 1 Year Buying-Selling Update And Now 5.8% Dividend Yield 
02/21UNDERVALUED AND ATTRACTIVE : Pick Up Novartis In 2018 
02/20BIOTECHS : Still Well Placed For More Gains 
Chart AMGEN
Duration : Period :
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Technical analysis trends AMGEN
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 196 $
Spread / Average Target 7,3%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Executive VP, Chief Financial & Accounting Officer
Sean E. Harper Executive Vice President-Research & Development
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN4.91%132 428
JOHNSON & JOHNSON-7.02%349 006
NOVARTIS-2.94%224 221
PFIZER-1.27%213 155
ROCHE HOLDING LTD.-9.41%207 327
MERCK AND COMPANY-3.06%148 618